The effects of LYCO on IL-1β, a marker of inflammation in colon tissues are presented in Figure 7A. The IL-1β level in the colon before IBD in the control group (no IBD, no LYCO) was 21.55 ± 3.74 pg/mg of protein. Here, IL1B is linked to inflammatory bowel disease.